A dose-response study in mice of a tetravalent recombinant dengue envelope domain III protein secreted from insect cells

Lijun Shao  
Weifang Medical University

Zheng Pang  
Tianjin International Joint Academy of Biotechnology and Medicine

Yu Bi  
Weifang Medical University

Zhenhua Li  
Weifang Medical University

Weiping Lin  
Weifang Medical University

Guolei Li  
Weifang Medical University

Mingling Wang  
Weifang Medical University

Yanming Guo  
Weifang Medical University

Guoyu Niu (✉ niugy@wfmc.edu.cn)  
Weifang Medical University

Research article

Keywords: Dengue virus, Tetravalent, Humoral immunity, Cellular immunity, Vaccine

Posted Date: January 15th, 2020

DOI: https://doi.org/10.21203/rs.2.20898/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License

Version of Record: A version of this preprint was published at Infection, Genetics and Evolution on November 1st, 2020. See the published version at https://doi.org/10.1016/j.meegid.2020.104427.
Abstract

Background: DENV is the most globally prevalent mosquito-transmitted virus. Induction of a broadly and potently immune response is desirable for dengue vaccine development.

Methods: We constructed a secreted tetravalent ED protein from eukaryotic cells and established a MAC-ELISA method for DENV diagnosis. This work aimed to evaluate the immune responses in mice of several formulations of rEDIII containing different amounts of the tetravalent protein.

Results: We demonstrated that the tetravalent protein induced humoral immunity against all four serotypes of DENV, even at the lowest dose assayed. Besides, cellular immunities against DENV-1 and DENV-2 were elicited by medium dose group. Importantly, the immune responses induced by the tetravalent formulation were functional in clearing DENV-2 in circulation of mice.

Conclusions: We believe that the tetravalent formulation of secreted ED protein is a potential vaccine candidate against DENV and suggest further detailed studies of this formulation in nonhuman primates.

Keywords: Dengue virus; Tetravalent; Humoral immunity; Cellular immunity; Vaccine

Background

Dengue virus infection is an arthropod-borne viral disease caused by dengue viruses which are transmitted by the bites of infected mosquitoes Aedes aegypti and Aedes albopictus [1, 2]. These viruses belong to the Flaviviridae family and contain a positive-sense single-strand RNA genome encoding three structural (C, prM and E) and seven nonstructural proteins [3]. Unlike other flaviviruses, there are four serotypes, referred to as DENV1, 2, 3, 4, that are genetically similar but antigenically distinct [4]. Owing to the wide distribution of mosquito vectors, more than 2.5 billion people, representing 40% of the world’s population, are at risk of dengue infection. In recent years, the geographical extension, number of cases, and disease severity of dengue have greatly increased, and it is estimated about 390 million dengue infections, of which 96 million manifest clinically and 22,000 deaths per year [5, 6].

Infection with any of the four DENV serotypes can result in a broad spectrum of clinical manifestations from a mild fever to classical dengue fever with hemorrhage (DHF) or dengue shock syndrome (DSS) [7, 8]. Primary infection with any one DENV serotype confers life-long immunity to that serotype, whereas secondary infection with a different serotype can cause the severe forms of the disease because of antibody-dependent enhancement (ADE) [9–11]. Hence, it is necessary for an effective DENV vaccine to induce a balanced and durable immune response specific for all four DENV serotypes simultaneously, avoiding the risk of severe disease through ADE. Several approaches for the research of tetravalent dengue vaccines are in different stages of development [12–19]. To date, the only DENV vaccine, Dengvaxia, from Sanofi-Pasteur, has been licensed in several dengue-endemic countries [20]. Nevertheless, this vaccine shows an overall efficacy of 60.3% and declined protection against DENV in seronegative vaccinees [21, 22], and is suspected to sensitise naive recipients to increased risk of
hospitalisation at later times [17]. Therefore, development of a tetravalent dengue vaccine inducing balanced and long-life immunity is still a huge challenge.

It is well established that the envelope protein is the major structural protein on the surface of the mature dengue virions, and the domain III region (DIII) of E protein is targeted by neutralizing antibodies in humans upon virus infection [23, 24]. Although there are some evidences showing domain III as an irrelevant target for neutralizing antibodies in humans [25, 26], vaccination with the domain III of the envelope protein indeed induces a neutralizing antibody response, conferring protection against re-infection [27–29]. In addition, DIII is involved in the recognition of the DENV receptor on target cells, and the cellular immune response should play an important role in the control of viral infection [30]. Taken together, the immunogenicity, protective capacity, and serotype specificity of DENV envelope protein DIII merits this antigen an ideal candidate for inducing a functional humoral and cell-mediated immune response.

In our previous study, we developed a tetravalent protein by connecting the receptor-binding envelope domain III (EDIII) of the four dengue virus serotypes using flexible peptide linkers, and found that the recombinant rEDIII protein was expressed successfully in Spodoptera frugiperda (sf9) lepidopteron cells and secreted into the supernatant of cell culture in a stable form with preserved native conformation. Based on these findings, we established and evaluated a MAC-ELISA method, which has potential utility in the diagnosis of dengue virus infections [31]. However, the immunogenicity of the tetravalent rEDIII protein was not fully studied. In the present study, we further analyzed the profile of humoral and cellular immune responses against DENV in mice after immunization with chimeric protein. Our results indicated that effective immune responses were generated in rEDIII-immunized mice, highlighting its functionality as a promising tetravalent dengue vaccine candidate, which could be potentially applied in DENV hyper-endemic areas.

**Methods**

**Cells and viruses**

African monkey kidney (Vero), K562 and C6/36 cells were kindly provided by Xiao-Hui Zou of the National Institute for Viral Disease Control and Prevention, China CDC, Beijing. Cells were grown at 37 °C in Eagle’s minimal essential medium (MEM) or RPMI medium supplemented with 10% heat-inactivated fetal bovine serum (FBS). The viral strains GZ (DENV-1), ZS (DENV-2), H-87 (DENV-3) and H241 (DENV-4) were used for the plaque-reduction neutralization test (PRNT), animal inoculation and animal challenge experiment. Virus propagation was implemented in C6/36 cell and viral titers were determined by plaque assay on Vero cells.

**Animals and ethics approval**

BALB/c mice (female, 6–8 weeks old) were purchased from Pengyue Laboratory Animal Co., Ltd. (Jinan), and housed in appropriate animal care facilities during the experimental period. The animals were kept at
the Laboratory Animal Center of Weifang Medical University. All of the mouse experiments were carried out in strict accordance with the guidelines of the Animal Committee of Weifang Medical University. The study was reviewed and approved by the Ethic Committee of Weifang Medical University. All mice were euthanized by cervical dislocation after the experiment. All sections of this report adhere to the ARRIVE Guidelines for reporting animal research. A completed ARRIVE guidelines checklist is included in Checklist S1.

Recombinant protein

The design, cloning, expression and purification of the tetravalent dengue protein were described previously [31]. In brief, the DIII regions were fused with linker to generate a rEDIII chimeric protein of each DENV serotype with a 6-His-tag at their C-terminal ends. The recombinant plasmid was transfected sf9 cells and the target protein was secreted into the supernatant culture. The supernatant fluid was clarified and subjected to chromatography on a Ni-NTA column attached to an AKTA purifier system (GE Healthcare Life Sciences, Sweden). At last, protein were collected and quantified. All recombinant protein were lyophilized and stored at -20 °C until use. The tetravalent formulations were prepared with different quantities of the rEDIII protein and incubated with 500 µg aluminum for 36 hours at 4 °C (on a rocking platform), clarified by centrifugation (5,000 rpm, 5 min) and re-suspended in 100 µl sterile 1 × PBS.

Animal experiments

The immunogen was injected by the intraperitoneal route into five groups of 16 female BALB/c mice on days 0, 15 and 45. Groups 1 to 4 received different tetravalent formulations containing rEDIII protein and aluminum adjuvant. Mice that were injected with aluminum alone (without vaccine candidates) served as negative controls. Blood and spleens of ten mice from each group were obtained for further immunological analysis 15 days after the last dose injection. Meanwhile, eight mice from each group were prepared for the animal challenge experiment. All sera were prepared and stored at -20 °C until use.

Measurement of humoral immune response

The presence of rEDIII-specific IgG in the sera was determined by enzymelinked immunosorbent assay (ELISA). A 2-fold serial dilution (starting at 1:10 for negative control or 1:100 for other groups) of each sample was prepared. Polystyrene 96-well plates (Costar, USA) were each coated with 100 µl of EDIII(D1-D4) protein (3 µg/mL) overnight at 4 °C in coating buffer (0.16% Na₂CO₃, 0.29% NaHCO₃, pH 9.5), respectively. Then they were blocked in coating buffer containing 5% skimmed milk for 1 h at 37 °C. After five washes with PBS containing 0.05% Tween 20 (PBS-T), 100 µl per well of sera from each group were tested by serial dilutions in PBS-T, starting at 1:5000. The sera of healthy mice were used as negative control. Plates were incubated for 1 h at 37 °C and washed as described above. Later, 100 µl per well of 1:30 000 diluted Goat anti mouse IgG peroxidase conjugate (Amersham Pharmacia, Beckinghamshire, UK) were added and the plates were incubated for 1 h at 37 °C. After washing, 100 µl per well of substrate, 3, 3', 5, 5'-tetramethylbenzidine (TMB), was added for color development. The plates were kept for 15 min at room temperature and the reaction was stopped with 50 µl per well of 2.5 M H₂SO₄.
Absorbance was read at 450 nm in a SensIdent Scan device (Merck, Helsinki, Finland). The positive cutoff value was set as twice the mean absorbance value of negative control sera.

Plaque reduction neutralization test

Neutralizing antibody titers were measured by plaque reduction neutralization test (PRNT) in Vero cells as previously described [32]. In brief, Vero cells (2 × 10^3 cells/well) were dispensed into 96-well plates and incubated for 16 h at 37 °C in a humidified 5% CO_2 environment. Equal amounts of diluted serum sample and diluted DENV were mixed and incubated at 37 °C for 1 h. Thereafter, 100 µl of the neutralized liquid was inoculated into three wells per dilution and allowed to adsorb for 36 h at 37 °C and 5% CO_2. Neutral red staining was then performed before final plaque counts were made. The neutralizing antibody titers were identified as the highest serum dilution that reduced the number of virus plaques by 50% (PRNT50) compared with control samples containing the virus alone. The sera were diluted by the continuous double dilution method starting at 1:2.

Measurement of cellular immune response

Mice were sacrificed and splenocytes were prepared 30 days after the third dose injection. The frequency and intensity of IFN-γ-producing cells were determined by mouse IFN-γ ELISPOT kits (Dakewe). All operations were conducted according to the manufacturer's procedures. In brief, 100 µl of IFN-γ-specific mAb was coated onto 96-well plates with PVDF membranes and incubated overnight at 4 °C. The plates were washed three times with PBS and blocked with RPMI medium supplemented with fetal bovine serum (10%) at 37 °C for 1 h to prevent nonspecific binding in later steps. The splenocytes were seeded at a concentration of 1 × 10^6 cells/well with each EDIII protein of DENV 1–4. Quadruplicate wells were set up for each stimulation and PBS or concanavalin A (5 µg/mL) were included as controls in parallel. After stimulation for 2 days at 37 °C in a 5% CO_2 humidified incubator, the cells were removed from the plates by washing five times with 0.05% (w/v) Tween 20 in PBS. Secondary biotin-conjugated antibody was added to each well and incubated at 37 °C for 2 h. The wells were washed five times with 0.05% Tween 20 in PBS, and peroxidase-labeled streptavidin was added at a 1:1000 dilution for 1 h. Then the plates were washed five times with 0.05% (w/v) Tween 20 in PBS and three times with PBS alone. Finally, a 100 µl aliquot of 3-amine-9-ethylcarbazole staining solution was added to each well to develop the spots. The reaction was stopped after 30 min by placing the plates under tap water. Plates were dried, and spots were counted under an ELISPOT reader. The results were expressed as the number of spot-forming units (SFU) per 10^6 splenocytes.

Animal challenge with DENV-2 infected K562 cells

Eight immunized mice from each group received an intraperitoneal injection of 5 × 10^7 DENV-2 infected K562 cells that were suspended in 0.5 mL of serum-free RPMI medium one month after the last dose injection, of which the mice immunized with aluminum (without vaccine candidates) were taken as negative control. One day after challenge, the mice were euthanized to measure viral loads in plasma by
quantiﬁcation on Vero cells. The blood (0.2 mL) was immediately mixed with 0.02 mL of 3.8% sodium citrate pre-chilled on ice. The plasma was isolated, and the viremia level was evaluated using PRNT with Vero cells.

Statistical analysis

Prism software version 5.00 (GraphPad Software, San Diego, CA, USA) was used for calculating the means, standard deviations, standard errors, and statistics analyses. Direct or transformed (Log2, Log10) data that passed the normality test (Kolmogorov–Smirnov or D'Agostino and Pearson omnibus normality test) and showed variance homogeneity (Bartlett's test) were analyzed by ANOVA parametric tests. Data that did not fulﬁl normality and/or variance homogeneity tests, even after transformations, were analyzed by the nonparametric test (Kruskal-Wallis test with LSD's multiple comparison tests). Differences with \( p < 0.05 \) were considered to be statistically signiﬁcant.

Results

The tetravalent rEDIII protein elicits a broad proﬁle of humoral immune responses in mice.

BALB/c mice were immunized with the rEDIII protein three times and antibody responses were monitored later. Serum samples were collected 15 days after the last immunization and tested for antibody responses against EDIII of all 4 serotypes by ELISA. All mice immunized with the tetravalent rEDIII protein developed an anti-EDIII IgG response against all four DENV serotypes (Fig. 1A-D). The anti-EDIII antibody titers of all cases were higher than \( 10^3 \), and no anti-EDIII antibody response were detected in animals from the aluminum group. As was expected, the strongest anti-EDIII antibody response with titers of all immunized animal groups exceeding \( 10^4 \) was detected against DENV-2. Statistical analysis showed a dose-response behavior. The immune response against D1EIII, D2EII, D4EIII measured in animals immunized with 50 µg of rEDIII had signiﬁcant differences compared with the lowest dose group (2 µg of rEDIII) (Fig. 1ABD). However, the response against D2EIII, D3EII, D4EIII detected in animals immunized with 50 µg of rEDIII was not statistical different from the response in the highest dose group (250 µg of rEDIII) (Fig. 1BCD). In general, animals receiving 50 µg of rEDIII showed a stronger response against all four DENV serotypes than those immunized with the lowest dose (\( p < 0.05 \)).

The capacity of the antibodies to neutralize dengue virus was evaluated using an in vitro neutralization test (PRNT). The results revealed that sera from rEDIII protein immunized animal neutralized in vitro viral infection with all four DENV serotypes (Fig. 2). The neutralizing antibody titer against dengue-3 or 4 was lower than that against dengue-1 or 2. Meanwhile, no neutralizing activity against DENV was detected in the sera of animals immunized with aluminum adjuvant. In accordance with the result of ELISA, the highest neutralizing activity was also detected against DENV-2. In addition, no statistical differences were observed between 10 µg and 50 µg groups in the neutralizing antibody titer measured against all four DENV serotypes.

The tetravalent rEDIII protein induces a cellular immune response in mice.
In order to evaluate the cellular immune response, spleen cells were collected 30 days after the last injection, and the frequency of IFN-γ producing in vitro stimulated with each EDIII protein was measured. Regardless of the dose of rEDIII protein, a positive IFN-γ secreting cell response was induced in immunized animals after in vitro stimulation with all four DENV EDIII antigens except D3EIII (Fig. 3). In general, the intensity of cell responses to D1EIII and D2EIII were much stronger than D3EIII and D4EIII. Be consistent with the humoral immune response, the highest frequency of IFN-γ-producing cells were observed in the group that medium dose of rEDIII assayed (10 µg or 50 µg), with values of 328.5 ± 103.8 or 314.8 ± 96.17 SFU/million cells for D2EIII. A lower frequency was detected in mice immunized with 2 or 250 µg of rEDIII, which showed a frequency of 100.1 ± 66.57 or 91.38 ± 77.94 SFU/million cells for D1EIII, 141.5 ± 74.75 or 174.4 ± 107.9 SFU/million cells for D2EIII and 33.25 ± 35.49 or 79 ± 103.5 SFU/ million cells for D4EIII. No antiviral IFN-γ secreting was observed in spleen cells from animals inoculated with aluminum adjuvant.

The tetravalent rEDIII protein significantly reduces viremia level in mice challenged with DENV-2. Mice are usually not the permissive hosts for DENV and artificial transient viremia can be developed by intraperitoneal injection of DENV infected K562 cells, which became a reliable indicator to evaluate the protective capacities of the candidate during dengue vaccine development [33]. In our study, this method was adopted to evaluate the efficiency of virus clearance in rEDIII protein immunized mice. 30 days after the last immunization, BALB/c mice of each group were challenged with DENV-2 infected K562 cells. As was expected, high viral loads were found in blood of mice immunized with the adjuvant, with a mean of $7.3 \times 10^5$ FFU/mL of DENV-2 (Fig. 4). However, the virus titers in the blood of rEDIII protein immunized mice were significantly lower than that from the adjuvant group. And there was a significant difference between each rEDIII protein immunized group and aluminum immunized group (p < 0.05). These results suggested that rEDIII protein immunized mice developed functional immune responses to clear DENV-2 from the circulation.

**Discussion**

The envelope protein (E protein) of DENV, especially its domain III (EDIII), is responsible for a wide range of biological activities, including binding to host cell receptors as well as fusion to and entry into host cells [34]. This domain, which is exposed and accessible on the virion surface and is involved in host cell surface receptor recognition, contains multiple type- and subtype-specific conformation-dependent neutralizing epitopes [35]. Therefore, the dengue E protein is an important antigen for diagnosis and vaccine development [36, 37]. Accumulating studies have proved that EDIII-based vaccine candidates can elicit specific neutralizing antibodies [38–40]. Choosing only domain III rather than whole envelope protein could reduce the risk of ADE due to the lack of other non-neutralizing or cross-reactive epitopes. Hence, most of recent efforts have focused on utilization of EDIII to produce a subunit dengue vaccine [41–43]. We have constructed a tetravalent domain III in tandem using the Gly4SerGly4 linker, and testified its potential utility in the diagnosis of DENV infections with a high degree of sensitivity and specificity [41].
In this study, we attempted to develop this tetravalent protein (rEIII) as vaccine candidates against DENV and evaluated the immune responses in mice.

Over recent years, recombinant envelope proteins of DENV have been successfully expressed in different systems including prokaryotic expression systems and eukaryotic expression systems, its defects are obvious. The major limitation lies in protein secretion, proteolytic processing and glycosylation. In the present report, the secreted rEDIII protein produced by baculovirus expression system was adopted as vaccine candidate in anti-dengue virus. This system had several advantages over most others, including (i) a secreted protein with greater flexibility and integrity of the tertiary structure, (ii) easier methods to purify, and thus (iii) higher yields. Our study was performed to assess the immunogenicity and protective capacity in mice with different doses, containing 2, 10, 50 and 250 µg of rEDIII protein mixed equivalents aluminum adjuvant.

Our results suggested that the tetravalent formulation could induce high antibody response against all four DENV EDIII antigens. Even the lowest dose (2 µg rEDIII) induced a positive antibody response showing good immunogenicity. Importantly, the antiviral antibodies elicited by all groups, 2, 10, 50 and 250 µg of rEDIII, showed neutralizing activity against all four serotypes of DENV. Dengue virus infection is a complex viral disease that caused by four serotypes. Viral interference has been reported when a dengue vaccine candidate composed of four live-attenuated DENVs was used [44, 45]. The occurrence of this interference may cause failure in providing adequate protection against all 4 serotypes [46]. In this study, 10 µg and 50 µg groups could elicit high and comparable affinity antibodies against all 4 serotypes of DENV, indicating that both groups were suitable for vaccine candidate. It should be pointed out that the neutralizing activities against dengue-3 and 4 did not quite match up to the high level against dengue-1 and 2, which probably due to the position located in the sequence (1-3-4-2) that may lead burying some crucial antigenic determinants inside. A longer linker was more appropriate to expose the most antigenic determinants of the four domain IIIs. Besides, the strongest activity was found in neutralizing antibodies against DENV-2. This is likely due to amino acid sequence differences of EDIIIs and the position of D2EIII in tetravalent protein. Similar results have been found in other studies [34, 47, 48].

Additionally, the secreting levels of IFN-γ in mouse spleen cells after stimulation with each DEIII were measured as a surrogate of the cellular immune response. The role of IFN-γ in anti-dengue infection has been widely reported [49, 50]. Sustained levels of IFN-γ in the serum of DENV-infected patients are correlated with anti-viral protection and induction of cytotoxic T-cell response [51, 52, 53]. Our results showed that no matter of the dose used, the rEDIII formulation induced obvious cellular immune responses against the D1EIII and D2EIII, suggesting the T-cell epitopes of D1EIII and D2EIII were fully recognized by mouse spleen cells. However, nearly no response against D3EIII and D4EIII was found, which might be attribute to that the T-cell epitopes were lost or buried inside of the rEDIII protein. Nevertheless, it cannot be ruled out that the activity of cellular response will depend on the cell line, the concentration of stimulant, and even the assay performed to assess this activity. Accumulated evidence indicated that the antigen dose plays a significant role in determining the quality of antigen-specific T cells. Recently research proved that a low dose of DENV antigen generates T cells with a high-avidity TCR,
whereas a high dose only induces T cells with a low-avidity TCR [54]. Similar but not identical results were observed in our study. Compared with the medium dose (10 µg or 50 µg), the high dose (250 µg) did inhibit the cellular immune response against D2EIII. However, no stronger response against D2EIII was induced in the low dose (2 µg) than in the medium dose.

Finally, the protective capacity of the rEDIII formulations was evaluated using a mouse model for DENV infection. Although mice are not the natural host of DENV, viremia levels could be detected within 10 min after injection by the intravenous route in mice [55]. However, it can be prolonged up to 1 day by challenging with DENV-infected K562 cells [33]. In this study, mice were challenged with K562 cells infected by DENV-2 because of its high immunogenicity and virulence. Measurement of virus titers in plasma 1 day after the challenge revealed a significant reduction of virus levels in rEDIII-immune mice compared to the control group. In accordance with the results of neutralization test and ELISPOT, the 10 µg and 50 µg groups manifested better virus clearance capacity than other groups. Considering more time was needed in virus-induced cellular immune response, neutralizing antibodies may play an important role in this process. These results suggested that rEDIII formulation induced functional immune responses in eliminating DENV-2 in vivo.

**Conclusions**

We evaluated the immune responses in mice to the rEDIII formulation and demonstrate that the tetravalent protein induced humoral immunity against all four serotypes of DENV and elicited cellular immunity against DENV-1 and DENV-2. Importantly, the immune responses induced by the tetravalent formulation were functional in clearing DENV-2 in circulation of mice. These represent important features on dengue vaccine development. Our findings showed the promising potential of this secreted protein in developing a tetravalent dengue vaccine candidate. Further studies should be conducted to evaluate the immunogenicity and protective capacity of rEDIII formulation in non-human primates.

**Abbreviations**

DENV  
dengue virus  
EDIII  
envelope domain III  
DHF  
dengue fever with hemorrhage  
DSS  
dengue shock syndrome  
ADE  
antibody-dependent enhancement  
PRNT  
plaque-reduction neutralization test
ELISA
enzyme-linked immunosorbent assay

Declarations

Ethical approval and consent to participate

The protocols were approved by the Committee on the Ethics of Animal Experiments of Weifang Medical University.

Consent for publication

Not applicable.

Availability of data and material

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Competing interests

The authors have declared that no competing interests exist.

Funding

This work was initiated and funded by the Shandong Province Higher Educational Science and Technology Program (J18KA176) and National Major Project for Infectious Disease Control and Prevention (2018ZX10731-101).

Authors’ contributions

L.S. and G.N. conceived and designed the experiments. Z.P., Y.B. and Z.L. performed the experiments. W.L. analysed the data. G.L. and M.W. contributed reagents, materials and analysis tools. Y.G., Z.P., L.S. and G.N. took part in the preparation and revision of the manuscript. All authors have given approval to the final version of the manuscript.

Acknowledgments

We acknowledge and thank Dr. Liu Yang of China CDC for his collaboration in article modification and Dr. Yu Li of Beijing CDC for his technical guidance.

References

1. Halstead SB. Dengue. Lancet. 2007; 370(9599): 1644-1652.
2. Guzman M G, Halstead SB, Harvey Artsob, Philippe Buchy, Jeremy Farrar, Duane J Gubler, et al. Dengue: a continuing global threat. Nature Reviews Microbiology. Nature Reviews Microbiology. 2010; 8(12supp): S7.

3. Rushika P, R J Kuhn. Structural proteomics of dengue virus. Current Opinion in Microbiology. 2008; 11(4): 369-377.

4. Schnettler E, Sterken M G, Leung J Y, Metz S W, Corinne Geertsema, Goldbach R W, et al. Noncoding flavivirus RNA displays RNA interference suppressor activity in insect and Mammalian cells. Journal of virology. 2012; 86(24): 13486-13500.

5. Guzman M G, E Harris. Dengue. Lancet. 2015; 385(9966): 453-465.

6. Bhatt S, Samir Bhatt, Gething P W, Brady O J, Messina J P, Farlow A W, Catherine L, et al. The global distribution and burden of dengue. Nature. 2013; 496(7446): 504.

7. Guzman M G, M Alvarez, S B Halstead. Secondary infection as a risk factor for dengue hemorrhagic fever/dengue shock syndrome: an historical perspective and role of antibody-dependent enhancement of infection. Archives of Virology. 2013; 158(7): 1445-1459.

8. Mairuhu A, Wagenaar J, Brandjes D, Van Gorp E. Dengue: an arthropod-borne disease of global importance. European journal of clinical microbiology and infectious diseases. 2004; 23(6): 425-433.

9. Goncalvez A P, Engle R E, Claire M S, Purcell R H, Lai C J. Monoclonal antibody-mediated enhancement of dengue virus infection in vitro and in vivo and strategies for prevention. Proceedings of the National Academy of Sciences. 2007; 104(22): 9422-9427.

10. Halstead S, J Chow, N Marchette. Immunological enhancement of dengue virus replication. Nature New Biology. 1973; 243(122): 24-25.

11. Halstead SB, Suresh Mahalingamet, Mary A Marovich, Sukathida Ubol, David M Mosser. Intrinsic antibody-dependent enhancement of microbial infection in macrophages: disease regulation by immune complexes. The Lancet infectious diseases. 2010; 10(10): 712-722.

12. Durbin A P, S S Whitehead. Dengue vaccine candidates in development. Current Topics in Microbiology and Immunology. 2010; 338(1): 129-143.

13. Maria Rosario Capeding, Ngoc Huu Tran, Sri Rezeki S Hadinegoro, Hussain Imam HJ Muhammad Ismail, Tawee Chotpitayasunondh, Mary Noreen Chua. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. The Lancet. 2014; 384(9951): 1358-1365.

14. Sabchareon A, Arunee Sabchareon, Wallace D, Sirivichayakul C, Limkittikul K, Chanthavanich P, Suvannadabba S. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. The Lancet. 2012; 380(9853): 1559-1567.

15. Villar L, Rivera-Medina D M, Arredondo-García J L, Boaz Mark, Starr-Spires L, Thakur M S. Safety and immunogenicity of a recombinant tetravalent dengue vaccine in 9-16 year olds: a randomized, controlled, phase II trial in Latin America. The Pediatric infectious disease journal. 2013; 32(10): 1102-1109.
16. Luis Villar, Gustavo Horacio Dayan, José Luis Arredondo-García, Doris Maribel Rivera, Rivaldo Cunha, Carmen Deseda. Efficacy of a tetravalent dengue vaccine in children in Latin America. New England Journal of Medicine. 2015; 372(2): 113-123.

17. Hadinegoro S R, Arredondo-García J L, Capeding M R, Deseda C, Chotpitayasunondh T, Dietze R. Efficacy and long-term safety of a dengue vaccine in regions of endemic disease. New England Journal of Medicine. 2015; 373(13): 1195-1206.

18. Coudeville L, N Baurin, and E Vergu. Estimation of parameters related to vaccine efficacy and dengue transmission from two large phase III studies. Vaccine. 2016; 34(50): 6417-6425.

19. Durbin A P, Kirkpatrick B D, Pierce K K, Carmoll M P, Tibery C M, Grier P L, et al. A 12-month-interval dosing study in adults indicates that a single dose of the national institute of allergy and infectious diseases tetravalent dengue vaccine induces a robust neutralizing antibody response. The Journal of infectious diseases. 2016; 214(6): 832-835.

20. Ferguson N M, Rodríguez-Barraquer I, Ilaria Dorigatti, Mier-Y-Teran-Romero L, Laydon D J, Cummings D A. Benefits and risks of the Sanofi-Pasteur dengue vaccine: Modeling optimal deployment. Science. 2016; 353(6303): 1033-1036.

21. Aguiar M N, Stollenwerk, Halstead S B. The risks behind Dengvaxia recommendation. The Lancet infectious diseases. 2016; 16(8): 882-883.

22. Halstead S B, Russell P K. Protective and immunological behavior of chimeric yellow fever dengue vaccine. Vaccine. 2016; 34(14): 1643-1647.

23. Crill W D, Roehrig J T, Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most efficient blockers of virus adsorption to Vero cells. Journal of virology. 2001; 75(16): 7769-7773.

24. Thullier P, Demangel C, Bedouelle H, Mégret F, Jouan A, Deubel V, et al. Mapping of a dengue virus neutralizing epitope critical for the infectivity of all serotypes: insight into the neutralization mechanism. Journal of General Virology. 2001; 82(8): 1885-1892.

25. Wahala W M, Kraus A A, Haymore L B, Accavitti-Loper M A, de Silva A M. Dengue virus neutralization by human immune sera: role of envelope protein domain III-reactive antibody. Virology. 2009; 392(1): 103-113.

26. Williams K L, Wahala W M P B, Orozco S, de Silva A M, Harris E. Antibodies targeting dengue virus envelope domain III are not required for serotype-specific protection or prevention of enhancement in vivo. Virology. 2012; 429(1): 12-20.

27. Hermida L, Bernardo L, Martín J, Alvarez M, Prado I, López C, et al. A recombinant fusion protein containing the domain III of the dengue-2 envelope protein is immunogenic and protective in nonhuman primates. Vaccine. 2006; 24(16): 3165-3171.

28. Gil L, Marcos E, Izquierdo A, Lazo L, Valdés I, Ambala P, et al. The protein DIIIIC-2, aggregated with a specific oligodeoxynucleotide and adjuvanted in alum, protects mice and monkeys against DENV-Immunology and cell biology. 2015; 93(1): 57-66.
29. White L J, Sariol C A, Mattocks M D, Wahala M P B W, Yingsiwaphat V, Collier M L, et al. An alphavirus vector-based tetravalent dengue vaccine induces a rapid and protective immune response in macaques that differs qualitatively from immunity induced by live virus infection. Journal of virology. 2013; 87(6): 3409-3424.

30. Chin J F, Chu J J, Ng M L. The envelope glycoprotein domain III of dengue virus serotypes 1 and 2 inhibit virus entry. Microbes and Infection. 2007; 9(1): 1-6.

31. Niu G, Pang Z, Guan C, Qi J, Li D, et al. Dengue virus envelope domain III protein based on a tetravalent antigen secreted from insect cells: Potential use for serological diagnosis. Virus research. 2015; 201: 73-78.

32. Morens D M, Halstead S B, Repik P M, Putvatana R, Raybourne N. Simplified plaque reduction neutralization assay for dengue viruses by semimicro methods in BHK-21 cells: comparison of the BHK suspension test with standard plaque reduction neutralization. Journal of clinical microbiology. 1985; 22(2): 250-254.

33. Yamanaka A, Konishi E. A simple method for evaluating dengue vaccine effectiveness in mice based on levels of viremia caused by intraperitoneal injection of infected culture cells. Vaccine. 2009; 27(28): 3735-3743.

34. Fahimi H, Mohammadipour M, Haddad Kashani H, Parvini F, Sadeghizadeh M. Dengue viruses and promising envelope protein domain III-based vaccines. Applied microbiology and biotechnology. 2018; 102(7): 2977-2996.

35. Ariën K K, Wilder-Smith A. Dengue vaccine: reliably determining previous exposure. The Lancet Global Health. 2018; 6(8): E830-E831.

36. Ludolfs D, Schilling S, Altenschmidt J, Schmitz H. Serological differentiation of infections with dengue virus serotypes 1 to 4 by using recombinant antigens. Journal of clinical microbiology. 2002; 40(11): 4317-4320.

37. Hapugoda M D, Batra G, Abeyewickreme W, Swaminathan S, Khanna N. Single antigen detects both immunoglobulin M (IgM) and IgG antibodies elicited by all four dengue virus serotypes. Clin. Vaccine Immunol. 2007; 14(11): 1505-1514.

38. Shuiping Chen, Man Yu, Tao Jiang, Yongqiang Deng, Chengfeng Qin, Ede Qin. Induction of tetravalent protective immunity against four dengue serotypes by the tandem domain III of the envelope protein. DNA and cell biology. 2007; 26(6): 361-367.

39. Fahimi H, Allahyari H, Hassan Z M, Sadeghizadeh M. Dengue virus type-3 envelope protein domain III; expression and immunogenicity. Iranian journal of basic medical sciences. 2014; 17(11): 836.

40. Leng C H, Liu S J, Tsai J P, Li Y S, Chen M Y, Liu H H, et al. A novel dengue vaccine candidate that induces cross-neutralizing antibodies and memory immunity. Microbes and Infection. 2009; 11(2): 288-295.

41. Gil L, Lazo L, Valdés I, Suzarte E, Yen P, Ramírez R, et al. The tetravalent formulation of domain III-capsid proteins recalls memory B-and T-cell responses induced in monkeys by an experimental dengue virus infection. Clinical & translational immunology. 2017; 6(6): e148.
42. McBurney S P, Sunshine J E, Gabriel S, Huynh J P, Sutton W F, Fuller D H, et al. Evaluation of protection induced by a dengue virus serotype 2 envelope domain III protein scaffold/DNA vaccine in non-human primates. Vaccine. 2016; 34(30): 3500-3507.

43. Poddar A, Ramasamy V, Shukla R, Rajpoot R K, Arora U, Jain S K, et al. Virus-like particles derived from Pichia pastoris-expressed dengue virus type 1 glycoprotein elicit homotypic virus-neutralizing envelope domain III-directed antibodies. BMC biotechnology. 2016; 16(1): 50.

44. Guy B, Barban V, Mantel N, Aguirre M; Gulia S; Pontvianne J, et al. Evaluation of interferences between dengue vaccine serotypes in a monkey model. The American journal of tropical medicine and hygiene. 2009; 80(2): 302-311.

45. Kanesa-thasan N, Sun W, Kim-Ahn G, Van Albert S, Putnak JR, King A, et al. Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers. Vaccine. 2001; 19(23-24): 3179-3188.

46. Swaminathan S, Khanna N, Herring B, Mahalingam S. Dengue vaccine efficacy trial: does interference cause failure? The Lancet infectious diseases. 2013; 13(3): 191-192.

47. Block O K T, Rodrigo W W S I, Quinn M; Jin X; Rose R C; Schlesinger J J. A tetravalent recombinant dengue domain III protein vaccine stimulates neutralizing and enhancing antibodies in mice. Vaccine. 2010; 28(51): 8085-8094.

48. Chiang C Y, Pan C H, Chen M Y, Hsieh C H, Tsai J P, Liu H H, et al. Immunogenicity of a novel tetravalent vaccine formulation with four recombinant lipidated dengue envelope protein domain III s in mice. Scientific reports. 2016; 6: 30648.

49. Shresta S, Kyle J L, Snider H M, Basavapatna M, Beatty P R, Harris E, et al. Interferon-dependent immunity is essential for resistance to primary dengue virus infection in mice, whereas T-and B-cell-dependent immunity are less critical. Journal of virology. 2004; 78(6): 2701-2710.

50. Prestwood T R, Morar M M, Zellweger R M, Miller R, May M M, Yauch L E, et al. Gamma interferon (IFN-γ) receptor restricts systemic dengue virus replication and prevents paralysis in IFN-α/β receptor-deficient mice. Journal of virology. 2012; 86(23): 12561-12570.

51. Gunther V J, Putnak R, Eckels K H, Mammen M P, Scherer J M, Lyons A, et Aal. A human challenge model for dengue infection reveals a possible protective role for sustained interferon gamma levels during the acute phase of illness. Vaccine. 2011; 29(22): 3895-3904.

52. Jeewandara C, Adikari T N, Gomes L, Fernando S, Fernando R H, Perera M K, et al. Functionality of dengue virus specific memory T cell responses in individuals who were hospitalized or who had mild or subclinical dengue infection. PLoS neglected tropical diseases. 2015; 9(4): e0003673.

53. Weiskopf D, Angelo M A, de Azeredo E L, Sidney J, Greenbaum J A; Fernando A N, et al. Comprehensive analysis of dengue virus-specific responses supports an HLA-linked protective role for CD8+ T cells. Proceedings of the National Academy of Sciences. 2013; 110(22): E2046-E2053.

54. Valdés I, Marcos E, Suzarte E, Pérez Y, Brown E, Lazo L, et al. A dose-response study in mice of a tetravalent vaccine candidate composed of domain III-capsid proteins from dengue viruses. Archives of virology. 2017; 162(8): 2247-2256.
55. Imoto J.-i, Konishi E, Dengue tetravalent DNA vaccine increases its immunogenicity in mice when mixed with a dengue type 2 subunit vaccine or an inactivated Japanese encephalitis vaccine. Vaccine. 2007; 25(6): 1076-1084.

**Figures**

**Figure 1**

Anti-EIII antibody responses induced by tetravalent recombinant dengue EDIII in mice. Four groups of BALB/c mice were intraperitoneally immunized with different formulations of the tetravalent recombinant dengue envelope protein domain III mixed with aluminum adjuvant. As a negative control, one group received equivalent amount of aluminum adjuvant. Fifteen days after the last dose, ten animals were bled and the IgG antibodies against D1EIII (A), D2EIII (B), D3EIII(C) and D4EIII (D) in sera were measured by ELISA. The charts plot mean with standard error media (n = 10). The dashed line represents the cutoff value. The statistical analysis was performed using Kruskal-Wallis One Way ANOVA and LSD's Multiple Comparisons tests (*p < 0.05). The results are representative of two independent experiments.
Figure 2

Neutralizing antibody responses induced by tetravalent recombinant dengue EDIII in mice. Fifteen days after the last dose, ten animals were bled and the neutralizing antibodies against DENV-1 (A), DENV-2 (B), DENV-3 (C) and DENV-4 (D) in sera were measured by PRNT. The charts plot mean with standard error media (n = 10). The dashed line represents the cutoff value. The statistical analysis was performed using Kruskal-Wallis One Way ANOVA and LSD's Multiple Comparisons tests (*p < 0.05; **p < 0.01; ***p < 0.001). The results are representative of two independent experiments.
Figure 3

Cell-mediated immune responses induced by tetravalent recombinant dengue EDIII in mice. One month after the last dose, spleen cells from the eight animals were stimulated in vitro with each EDIII. The frequency of IFN-γ-secreting cells in spleens was measured by ELISPOT after in vitro stimulation with D1EIII (A), D2EIII (B), D3EIII (C) and D4EIII (D). The dashed line indicates the cutoff. The statistical analysis was performed using Kruskal-Wallis One Way ANOVA and LSD's Multiple Comparisons tests (*p < 0.05; **p < 0.01; ***p < 0.001). Data represent the mean± standard error from total 8 mice of two independent experiments. The results are expressed as the number of spot-forming units (SFU) per 10^6 splenocytes.
Figure 4

Reduction of viremia levels in vaccinated mice after challenged with DENV-2. Mice were intraperitoneally challenged with $5 \times 10^7$ DENV-2 infected K562 cells at one month after the last vaccination. One day after challenge, the mice were euthanized to measure viral loads in plasma by quantification on Vero cells. The charts plot mean with standard error media ($n = 8$). The dashed line represents the cutoff value. The statistical analysis was performed using Kruskal-Wallis One Way ANOVA and LSD’s Multiple Comparisons tests ($***p < 0.001$). The results are representative of two independent experiments.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- NC3RsARRIVEGuidelinesChecklist2014.docx